Standard BioTools Inc(LAB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.23 | Insider Own | 4.08% | Shs Outstand | 392.1M | Perf Week | 0.73% |
| Market Cap | 0.24B | Forward P/E | - | EPS next Y | -60% | Insider Trans | - | Shs Float | 378.6M | Perf Month | -16.24% |
| Enterprise Value | -0.21B | PEG | - | EPS next Q | -0.02 | Inst Own | 74.82% | Short Float | 0.65% | Perf Quarter | -29.58% |
| Income | -0.09B | P/S | 2.85 | EPS this Y | 33.33% | Inst Trans | -3.18% | Short Ratio | 1.94 | Perf Half Y | -34.79% |
| Sales | 0.08B | P/B | 0.44 | EPS next 5Y | - | ROA | -9.11% | Short Interest | 2.45M | Perf YTD | -52.34% |
| Book/sh | 1.38 | P/C | 0.51 | EPS past 3/5Y | 56.76% 23.22% | ROE | -11.18% | 52W High | -64.53% ($1.72) | Perf Year | -46.96% |
| Cash/sh | 1.21 | P/FCF | - | Sales past 3/5Y | -4.49% -9.19% | ROIC | -15.54% | 52W Low | 3.72% ($0.59) | Perf 3Y | -68.39% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 29.58% | Gross Margin | 49.14% | Volatility(W/M) | 4.77% 6.37% | Perf 5Y | -88.16% |
| Dividend TTM | - | EV/Sales | -2.46 | Sales Y/Y TTM | -45.15% | Oper. Margin | -74.04% | ATR (14) | 0.04 | Perf 10Y | -86.29% |
| Dividend Ex-Date | - | Quick Ratio | 8.8 | EPS Q/Q | 22.07% | Profit Margin | -103.29% | RSI (14) | 38.22 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.1 | Sales Q/Q | -7.62% | SMA20 | -6.11% ($0.65) | Beta | 1.5 | Target Price | $1.35 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/5 | SMA50 | -10.34% ($0.68) | Rel Volume | 0.8 | Prev Close | $0.62 |
| Employees | 389 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | -446.88% -3.37% | SMA200 | -33.37% ($0.92) | Avg Volume(3M) | 1.26M | Price | $0.61 |
| IPO | 2011/2/10 | Option/Short | Yes/Yes | Trades | 2450 | Volume | 1,002,545 | Change | -1.61% |
The company supplies life science research tools spanning single-cell analysis and proteomics. Leveraging microfluidics and mass cytometry (CyTOF) technology, it provides instruments and consumables to academic, pharmaceutical, and biotech research institutions, and has established a differentiated position in the precision life science tools space.
Over the past 1 year, on the lower side
65% below its 1-year high.
Traded about as much as usual. That is 80% of its average volume.
LAB has a sound balance sheet but weak earning power
Of every $100 in sales, $74.04 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +33.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $285. Peers typically go for $143.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 74.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% 
GNOM Global X Genomics & Biotechnology ETF <0.01% 
IWC iShares Micro-Cap ETF <0.01% 
IWN iShares Russell 2000 Value ETF <0.01% 
IBB iShares Biotechnology ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
ACYN FT Vest Laddered Autocallable Barrier & Income ETF 2.7B 
CAIE Calamos Autocallable Income ETF 1.5B 
ACYS FT Vest Laddered Autocallable Barrier & Resilient Income ETF 637M 
CAIQ Calamos Nasdaq Autocallable Income ETF 417M 
CAGE Calamos Autocallable Growth ETF 187M It ranks #73 of 142 in the industry
Based on market cap of $241M.
INFU#72 InfuSystem Holdings Inc $280M PER 34.5 LAB#73 Standard BioTools Inc $241M PER - 
PROF#74 Profound Medical Corp $240M PER - 
TLSI#75 TriSalus Life Sciences Inc $228M PER - 
ELMD#76 Electromed Inc $224M PER 20.8 
FAQ
What kind of company is LAB?
LAB belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of LAB?
The market cap of LAB is approximately $241M, ranking 3,862 within its sector.
What is the 52-week high and low for LAB?
LAB has recorded a 52-week high of $1.72 and a low of $0.59.
